Strategic Market Intelligence Report: Global Leaders in Deep Brain Stimulation and Methamphetamine Cessation Therapeutics (2025–2030)

Executive Summary

The global neurological and psychiatric treatment landscape is currently undergoing a bifurcation between mature, device-driven interventions for movement disorders and nascent, pharmacological explorations for substance use disorders. This report provides an exhaustive analysis of two specific high-value domains: the oligopolistic market of Deep Brain Stimulation (DBS) devices and the emerging, high-stakes pipeline for Methamphetamine Use Disorder (MUD) cessation therapeutics.

As of the 2025–2026 fiscal cycle, the DBS market represents a mature industrial sector characterized by incremental yet highly sophisticated technological competition among three primary incumbents: **Medtronic**, Abbott Laboratories, and Boston Scientific. Collectively, these entities control over 90% of the global market, competing on the axes of directionality, sensing capabilities, and remote care ecosystems. The market is currently valued between USD 1.4 billion and USD 1.6 billion, with a trajectory to exceed USD 2.5 billion by 2030, driven by an aging global population and the commercialization of "closed-loop" adaptive systems.[1]

Conversely, the Methamphetamine cessation market is defined by a critical clinical void. Despite methamphetamine overdose deaths tripling in recent five-year blocks and usage rates climbing in North America and Southeast Asia, there remains no FDA-approved medication for this indication as of early 2026.[3] "Market leadership" in this sector is therefore categorized not by sales revenue, but by clinical evidence strength. The combination of Naltrexone and Bupropion (validated by the ADAPT-2 trial) serves as the de facto standard of care, while a diverse pipeline of biotechnology firms—including InterveXion Therapeutics (immunotherapy), **Solvonis (psychedelic-assisted therapy)**, and BioCorRx (implantable adherence solutions)—race to secure the first regulatory approval.[6]

Part I: The Global Deep Brain Stimulation (DBS) Market

1. Market Overview and Structural Dynamics

The Deep Brain Stimulation market operates as a high-barrier, capital-intensive oligopoly. The complexity of Class III medical device engineering, combined with the rigorous requirements of neurosurgical clinical trials, has entrenched a "Big Three" hierarchy that has remained stable for over a decade.

1.1 Market Size and Financial Forecasts

The global valuation of the DBS market in 2024 was estimated at approximately USD 1.40 billion to USD 1.61 billion.[1] Financial projections indicate a robust growth phase over the next five years, with compound annual growth rates (CAGR) estimated between 9.8% and 11.45%.[1] By 2030, the market is expected to reach a valuation of USD 2.50 billion to USD 3.5 billion, depending on the rate of adoption for emerging indications such as epilepsy and Alzheimer's disease.[1]

This growth is not uniform across all geographies or segments.

- **North America:** Remains the dominant revenue generator, accounting for 50.55% of the global market share in 2024.[1] The dominance of the U.S. market is underpinned by established reimbursement codes (CPT) for both implantation and programming, as well as a high density of specialized movement disorder clinics.
- **Asia-Pacific:** This region is projected to register the highest CAGR (11.45%) through 2030.[9] The growth is driven by increasing healthcare expenditure in China and Japan, rising awareness of Parkinson's Disease treatments, and the entry of local competitors offering cost-effective alternatives.
- **Segment Trends:** The dual-channel segment (devices capable of stimulating both hemispheres of the brain) dominates the market with a 56.9% share, reflecting the bilateral nature of Parkinson's symptoms.[1]

1.2 The Competitive Landscape

The market is intensely concentrated. While niche players like Renishaw PLC (UK), Aleva Neurotherapeutics (Switzerland), and Beijing Pinchi (China) exist, the global market is effectively controlled by Medtronic, Abbott, and Boston Scientific.[9] Competition has shifted from basic efficacy—which is relatively comparable across brands—to "quality of life" features for the patient (battery life, size) and "workflow" features for the clinician (programming speed, data visibility).

---

2. Medtronic: The Pioneer and Data Ecosystem Leader

Medtronic holds the distinction of being the pioneer of DBS therapy, having received the first

FDA approval in 1997.[12] In the 2025 landscape, Medtronic has successfully pivoted from being a hardware-centric legacy player to a data-centric innovator. Their strategy revolves around the integration of sensing technology to create a proprietary ecosystem that differentiates their offering from competitors who focus primarily on stimulation delivery.

2.1 The Percept™ Ecosystem and BrainSense™ Technology

Medtronic's flagship product lines, the **Percept™ PC** (primary cell/non-rechargeable) and **Percept™ RC** (rechargeable), are built on the proprietary **BrainSense™** platform.[13] This technology represents a fundamental paradigm shift in neuromodulation.

Traditionally, DBS devices were "open-loop" systems: they delivered electrical pulses blindly, without feedback from the brain. BrainSense enables the Percept device to capture and record **Local Field Potentials (LFPs)**—oscillatory electrical signals produced by populations of neurons.[15] In Parkinson's Disease, specific frequency bands (beta bands) correlate with the severity of motor symptoms like rigidity and bradykinesia. By recording these signals, the Percept device provides clinicians with objective data on the patient's brain state outside the clinic, allowing for evidence-based programming rather than trial-and-error adjustments.

Percept™ RC Specifications:

- **Approval Status:** Received FDA approval in January 2024 and TGA approval in late 2024.[13]
- **Form Factor:** It is marketed as the smallest and thinnest dual-channel rechargeable neurostimulator on the market.[14]
- **Battery Chemistry:** The device boasts a service life of at least 15 years, addressing a major concern regarding repeated surgical replacements.[14]
- **Charging Capability:** Medtronic's data suggests that 50th percentile usage requires recharging every 12 days, while higher energy usage (80th percentile) requires recharging every 9 days.[15] This is a critical metric for patient quality of life.

2.2 The Era of Adaptive DBS (aDBS)

In February 2025, **Medtronic achieved a historic regulatory milestone by earning U.S. FDA approval for the world's first Adaptive Deep Brain Stimulation (aDBS) system for people with Parkinson's.**[18]

Seems odd that this is only approved for parkinsons

- **Mechanism:** unlike standard DBS, which delivers constant stimulation 24/7, aDBS automatically adjusts the strength of stimulation in real-time response to the detected brain signals (LFPs). If the device detects rising beta-band activity (indicating an oncoming tremor or stiffness), it increases therapy. If signals normalize, it decreases therapy.[12]
- **Clinical Impact:** This dynamic adjustment is designed to prevent over-stimulation (which

can cause dyskinesia or speech problems) and under-stimulation (breakthrough symptoms), effectively "smoothing out" the patient's day-to-day experience.[12]

2.3 SenSight™ Directional Lead System

To facilitate sensing, Medtronic introduced the **SenSight**™ lead system, the first directional lead designed specifically for the sensing environment.[19]

- **Signal Integrity:** Standard leads can introduce electrical noise that obscures the tiny LFP signals (which are one million times smaller than stimulation pulses). SenSight leads use precise material engineering to maintain signal clarity.[16]
- **1-3-3-1 Configuration:** The leads utilize a specific electrode spacing (1-3-3-1) that allows for precise directional steering of the electrical field, helping surgeons target the Subthalamic Nucleus (STN) or Globus Pallidus (GPi) while avoiding adjacent structures.[16]

---

3. Abbott Laboratories: The Patient-Centric Challenger

Abbott Laboratories entered the DBS market later than Medtronic (via the acquisition of St. Jude Medical) but has rapidly captured market share by focusing on the "consumerization" of the medical device. Their strategy prioritizes patient convenience, aesthetic discretion, and remote connectivity, directly addressing the "burden of therapy" that deters many eligible patients from undergoing surgery.

3.1 Liberta RC™: Minimizing the Implant Footprint

The cornerstone of Abbott's 2025 portfolio is the **Liberta RC**™ DBS system, which received FDA approval in January 2024.[10]

- **Size Advantage:** Abbott markets Liberta RC as the world's smallest rechargeable DBS implantable pulse generator (IPG), with a volume approximately 31% smaller than competitive devices available in the U.S..[20] This reduction in size is clinically significant for patients with low body mass index (BMI) or those concerned about the visibility of the implant under the skin (the "pacemaker bulge").
- **Battery Superiority:** A critical competitive differentiator is the recharge interval. Abbott claims the Liberta RC has the longest-lasting battery charge of any FDA-approved DBS system. Under standard settings, the device can operate for **37 days** between charges.[12]
- **Lifestyle Impact:** This translates to a requirement of only approximately 10 recharge sessions per year for most people, compared to the weekly or bi-weekly rituals required by older systems or competitor devices.[20] This dramatic reduction in "charging anxiety" is a primary selling point for the device.

3.2 Infinity™ and Directional Steering

Abbott also offers the **Infinity**™ DBS system, which features directional leads. While Medtronic also offers directionality (SenSight), Abbott was an early mover in this space with segmented

leads that allow clinicians to "steer" the electrical current away from side-effect-causing areas.[12]

3.3 NeuroSphere™ Virtual Clinic: The Remote Care Moat

Abbott's most significant strategic advantage lies in its software ecosystem, specifically the **NeuroSphere™ Virtual Clinic**.

- **Telehealth Integration:** This FDA-approved platform allows patients to connect with their neurologist via a secure mobile app. Crucially, it allows the physician to **remotely adjust stimulation settings** in real-time while seeing the patient over video.[21]
- **Addressing Access Barriers:** Research indicates that the average DBS patient in the U.S. travels over 150 miles to see a movement disorder specialist.[20] NeuroSphere eliminates the need for these arduous trips for routine programming adjustments, democratizing access to expert care for rural and mobility-impaired patients.
- **Competitive Positioning:** While Medtronic focuses on *automated* adjustments inside the body (aDBS), Abbott focuses on facilitating the *human* connection between doctor and patient across distances.

---

4. Boston Scientific: The Precision Innovator

Boston Scientific (BSC) occupies the position of the "precision engineer" in the DBS oligopoly. Their technological heritage, derived partly from cochlear implant technology, emphasizes the precise physics of electrical field shaping.

4.1 Vercise Genus™ Platform

The **Vercise Genus™** family (including the R16 rechargeable and P16 non-rechargeable models) represents BSC's fourth generation of DBS technology.[22]

- **Multiple Independent Current Control (MICC):** This is BSC's defining feature. Most DBS systems utilize a single power source that is shared across active contacts. Vercise Genus utilizes independent current sources for each electrode contact. This allows for **fractionation** of current, enabling the surgeon to "sculpt" the electrical field with extreme precision.[1]
- **Clinical Utility:** This precision is vital when the lead is placed slightly off-target. MICC allows the clinician to electronically "steer" the stimulation field back toward the target and away from the internal capsule (which causes muscle contractions) or the optic tract (which causes visual flashes).[23]

4.2 Cross-Compatibility and Replacement Strategy

Boston Scientific has adopted an aggressive strategy regarding device interoperability. They market their IPGs as being compatible with leads from other manufacturers (specifically Medtronic and Abbott).[24]

- **The "Socket" War:** When a patient with a Medtronic or Abbott device needs a battery replacement (typically every 3-5 years for non-rechargeables), Boston Scientific encourages surgeons to switch the IPG to a Vercise Genus while leaving the original leads in the brain. This allows patients to upgrade to BSC's precision technology without the risks of intracranial surgery.[24]
- ***Battery Longevity: Like Medtronic, BSC claims a battery service life of at least 15 years for its rechargeable R16 model.***[12]

4.3 MRI and Visualization

BSC collaborates with **Brainlab** to offer advanced visualization software, allowing clinicians to see the patient's specific brain anatomy and the estimated electrical field in 3D. The system is also **ImageReady**™ MRI conditional, allowing for full-body scans under specific safety conditions.[15]

---

5. Comparative Analysis: Technical Specifications (2025)

The following table provides a direct comparison of the flagship rechargeable systems from the three market leaders, based on 2024-2025 data.

Feature	Medtronic Percept™ RC	Abbott Liberta RC™	Boston Scientific Vercise Genus™ R16
Primary Advantage	**Sensing (BrainSense) & Adaptation:** The only system capable of recording brain signals (LFP) and auto-adjusting therapy (aDBS).	**Size & Battery Interval:** Smallest device volume; longest time between charges (37 days).	**Precision (MICC):** Independent current control allows for the most granular field steering/shaping.
Battery Life (Service)	15+ years	15+ years	15 years
Recharge Frequency	Every 9-12 days (typical usage) [15]	Every 37 days (typical usage); ~10 times/year [20]	Variable; dependent on settings.

Lead Technology	**SenSight™:** Directional + Sensing (1-3-3-1 spacing).	**Infinity™:** Directional leads.	**Cartesia™:** Directional leads with independent control.
Remote Care	CareLink (Data monitoring)	**NeuroSphere™:** Full remote programming & video visit.	Available (Remote control adjustments).
MRI Safety	Full-body 1.5T & 3T conditional.[16]	Full-body MRI conditional.[15]	Full-body MRI conditional (ImageReady).[15]
Market Share (Est.)	~50% (Global Leader) [1]	~30-35% (Rapid Growth)	~15-20% (Stable Niche)

Part II: Methamphetamine Cessation Therapeutics – The Emerging Market

While the DBS market is defined by technological maturity and incremental innovation, the market for Methamphetamine Use Disorder (MUD) therapeutics is defined by high unmet need, biological complexity, and a "wild west" of off-label prescribing. As of early 2026, the FDA has not approved a single medication for the treatment of methamphetamine addiction.[3]

6. The Clinical and Economic Imperative

Methamphetamine usage has surged to epidemic proportions in many regions.

- **Public Health Crisis:** In the United States, overdose deaths involving psychostimulants (primarily methamphetamine) tripled from 2015 to 2019.[26]
- **Global Spread:** The World Drug Report 2025 highlights that methamphetamine markets are expanding in South-East Asia and North America, with production reaching all-time highs.[5]
- **The Treatment Gap:** Unlike Opioid Use Disorder (OUD), which has three FDA-approved classes of medication (Methadone, Buprenorphine, Naltrexone), MUD has none. This is partly due to the mechanism of the drug: methamphetamine causes massive release of dopamine, norepinephrine, and serotonin, and is directly neurotoxic to nerve terminals.[25] Reversing this damage or blocking the effect without causing severe side effects has proven pharmacologically difficult.

In this vacuum, "market leadership" is held by those therapies that have demonstrated efficacy in large-scale clinical trials, even without formal regulatory approval.

---

7. The De Facto Standard of Care: Naltrexone + Bupropion

In the absence of a novel patented drug, a combination of two generic medications has emerged as the clinical front-runner: **Injectable Naltrexone** (an opioid antagonist) and **Oral Bupropion** (an antidepressant/stimulant-like drug).

7.1 The ADAPT-2 Clinical Trial

The efficacy of this combination was established by the pivotal **ADAPT-2** trial (NCT03078075), a multi-site study funded by the National Institute on Drug Abuse (NIDA).[6]

- **Study Design:** The trial utilized a sequential parallel design with 403 participants. Patients received either extended-release injectable naltrexone (administered every 3 weeks) plus daily oral extended-release bupropion (450 mg), or matched placebos.[27]
- **Efficacy Data:** The study found that **13.6%** of participants in the treatment group had a positive response (defined as at least 3 out of 4 negative urine tests at the end of the stage) compared to only **2.5%** in the placebo group.[4]
- **Analysis:** While a 13.6% response rate appears low compared to other medical treatments, in the context of severe addiction, this represented a highly statistically significant improvement (Number Needed to Treat = 9). Furthermore, secondary analyses published in 2024/2025 showed that the treatment significantly reduced the *frequency* of use even in those who did not achieve total abstinence.[28]

7.2 Mechanism of Action

The synergy of these two drugs addresses the dual nature of addiction:

1. **Bupropion:** Inhibits the reuptake of dopamine and norepinephrine. This helps to normalize the "dopamine deficit" that occurs during meth withdrawal, reducing the dysphoria, fatigue, and anhedonia that often trigger relapse.[30]
2. **Naltrexone:** Blocks the mu-opioid receptors. Although meth is not an opioid, the endogenous opioid system is involved in the reinforcing properties of stimulants. Naltrexone helps to "blunt" the craving and the reward if the patient does use.[30]

Market Status: Because these drugs are generic (Bupropion) or established brands (Vivitrol), there is no single "manufacturer" driving this as a blockbuster product. However, clinical guidelines are increasingly citing this combination as the first-line pharmacological option.[30]

---

8. The Biotech Pipeline: Innovation and Novel Mechanisms

Several biotechnology companies are racing to develop the first FDA-approved medication specifically for MUD. These companies are generally supported by NIDA grants, as the commercial risk is considered high by large pharma.

8.1 InterveXion Therapeutics: The Biological Blockade

InterveXion Therapeutics is a leader in the development of monoclonal antibodies for addiction. Their lead candidate, **IXT-m200**, represents a fundamentally different approach to treatment.[7]

- **Mechanism (Pharmacokinetic Antagonism):** IXT-m200 is a high-affinity monoclonal antibody that binds to methamphetamine in the bloodstream. The antibody-drug complex is too large to cross the blood-brain barrier. Therefore, the antibody acts as a "peripheral sink," sequestering the drug in the blood and preventing it from reaching the brain to cause a high.[7]
- **Clinical Status:** The drug received **FDA Fast Track Designation**. InterveXion launched the **STAMPOUT** and **OUTLAST** Phase 2 trials to test safety and efficacy.[31]
- **Challenges:** The **OUTLAST** trial (NCT05034874) was terminated early according to clinical registry updates in late 2024. The reason cited was that the "interim analysis concluded planned study numbers combined with participant dropout rates were insufficient to meet primary endpoint".[32] Despite this setback, the approach remains a primary focus of NIDA funding, as it avoids the side effects of drugs that act on the brain.[33]

8.2 Solvonis (formerly Awakn Life Sciences): Psychedelic-Assisted Therapy

Following its acquisition of **Awakn Life Sciences** in May 2025, **Solvonis Therapeutics** has positioned itself as the leader in the commercialization of **Ketamine-Assisted Psychotherapy** for addiction.[8]

- **Lead Candidate: SVNS-001** (formerly AWKN-001).
- **Mechanism:** Ketamine is an NMDA receptor antagonist. At sub-anesthetic doses, it increases neuroplasticity (the brain's ability to form new connections) and Brain-Derived Neurotrophic Factor (BDNF). Solvonis utilizes this "plastic window" to administer manualized Cognitive Behavioral Therapy (CBT), helping patients break the rigid neural patterns of addiction.[34]
- **Expansion to Methamphetamine:** While their Phase 3 trial is currently focused on severe Alcohol Use Disorder (AUD), Solvonis has explicitly expanded its pipeline to include MUD. In late 2025, their program for Methamphetamine and Cocaine addiction was accepted into the NIDA-funded Addiction Treatment Discovery Program.[35]
- **KARE Trial Context:** Solvonis builds on data from the **KARE** trials (Ketamine for reduction of Alcohol Relapse), translating the protocol to stimulant use disorder.[34]

8.3 BioCorRx: Implantable Adherence Solutions

BioCorRx Inc. addresses a critical failure point in addiction treatment: patient non-compliance. Methamphetamine users often lead disorganized lives, making daily pill regimens (like Bupropion) difficult to maintain.

- **Lead Candidate: BICX104**.
- **Technology:** This is a biodegradable, implantable pellet of Naltrexone that is placed under the skin. It provides sustained release of the medication for several months.[36]
- **Strategic Logic:** By removing the daily decision to take medication, BICX104 ensures that the "blocking" effect of Naltrexone is always present. BioCorRx has received significant funding from NIDA/NIH to develop this specifically for MUD.[37]
- **Status:** Phase 1 trials demonstrated sustained delivery over 12 weeks. The company is currently progressing through Phase 2 regulatory pathways.[36]

8.4 Emerging Candidates and "Wildcards"

- **Sen-Jam Pharmaceutical:** Developing **SJP-005**, a combination drug targeting neuroinflammation. They recently filed a patent (Oct 2025) for stimulant withdrawal, positioning inflammation as a "root cause" of addiction symptomatology.[26]
- **Panacea Life Sciences & University of Florida:** In December 2025, researchers identified a link between meth addiction and **Tumor Necrosis Factor-alpha (TNF-alpha)**, a pro-inflammatory protein. Meth triggers TNF-alpha, which in turn potentiates dopamine release. Panacea is investigating the use of existing anti-inflammatory drugs to break this cycle.[39]
- **Mirtazapine:** Clinical trials (e.g., NCT04614584) have investigated Mirtazapine (an antidepressant) for MUD. It has shown particular promise in reducing use among men who have sex with men (MSM), a key demographic for meth use.[41]

Part III: Strategic Convergence – Neuromodulation Meets Addiction

The most futuristic and potentially disruptive trend is the convergence of the two markets discussed in this report: the use of Deep Brain Stimulation hardware (from Part I) to treat the addiction indications (from Part II).

9.1 DBS for Refractory Addiction

While currently experimental, DBS is being investigated for patients with severe, treatment-resistant substance use disorders.

- **Target:** The **Nucleus Accumbens (NAc)**, the brain's central reward hub, is the primary target.
- **Mechanism:** High-frequency stimulation may "normalize" the activity of the reward circuit, reducing the intense cravings that drive relapse.

- **Activity:** The **Focused Ultrasound Foundation** launched a trial in 2025 using focused ultrasound (a non-invasive lesioning technique) for methamphetamine addiction.[42] If this target proves effective, it validates the pathway for invasive DBS.
- **Commercial Implication:** If DBS is approved for addiction, **Medtronic** would have a massive advantage. Their **Percept** device with **BrainSense** could theoretically detect the neural signature of a "craving" (e.g., a specific beta/gamma burst in the NAc) and deliver a burst of stimulation to disrupt it before the patient relapses. This "closed-loop craving management" represents the ultimate convergence of the two fields.

Conclusion

The markets for Deep Brain Stimulation and Methamphetamine Cessation are at opposite ends of the maturity spectrum but are driven by the same fundamental force: the urgent need to modulate the brain's malfunctioning circuitry.

For **Deep Brain Stimulation**, the 2025–2030 period will be defined by the "Intelligence Wars." **Medtronic** has set the new standard with **Adaptive DBS**, forcing competitors to respond with their own sensing and automation capabilities. **Abbott** will continue to win on patient lifestyle and remote access, while **Boston Scientific** will retain the surgeon-centric segment with its precision field shaping.

For **Methamphetamine Cessation**, the industry is in a pre-commercial "gold rush." While **Naltrexone/Bupropion** holds the fort as the off-label standard, the race is on for the first FDA approval. **InterveXion's** antibody approach offers a "vaccine-like" solution, while **Solvonis** bets on the psychological breakthrough of psychedelics.

Ultimately, the lack of effective pharmaceutical options for meth addiction may drive the adoption of device-based therapies, bringing the titans of the DBS world into the addiction space and creating a new, multi-billion dollar frontier in bio-electronic medicine.

Works cited

1. Deep Brain Stimulation Devices Market | Industry Report 2030 - Grand View Research, accessed on January 17, 2026, https://www.grandviewresearch.com/industry-analysis/deep-brain-stimulators-dbs-market
2. Deep Brain Stimulation Devices Market Size, Report by 2034 - Precedence Research, accessed on January 17, 2026, https://www.precedenceresearch.com/deep-brain-stimulation-devices-market
3. Study Details | NCT06233799 | Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder | ClinicalTrials.gov, accessed on January 17, 2026, https://www.clinicaltrials.gov/study/NCT06233799
4. Naltrexone-Bupropion Combination May Reduce Methamphetamine Use |

Psychiatric News, accessed on January 17, 2026, https://psychiatryonline.org/doi/full/10.1176/appi.pn.2021.3.17
5. World Drug Report 2025 - UNODC, accessed on January 17, 2026, https://www.unodc.org/documents/data-and-analysis/WDR_2025/WDR25_B1_Key_findings.pdf
6. Testing the combination of bupropion and extended-release naltrexone for methamphetamine use disorder - Recovery Research Institute, accessed on January 17, 2026, https://www.recoveryanswers.org/research-post/testing-combination-bupropion-extended-release-naltrexone-methamphetamine-use-disorder/
7. NIH Awards $13.8 Million to Test UAMS-Discovered Drug for Methamphetamine Use Disorder Treatment, accessed on January 17, 2026, https://news.uams.edu/2021/11/01/nih-awards-13-8-million-to-test-uams-discovered-drug-for-methamphetamine-use-disorder-treatment/
8. Completion of the acquisition of Awakn Life Sciences Corp - Solvonis Therapeutics, accessed on January 17, 2026, https://solvonis.com/news/completion-of-the-acquisition-of-awakn-life-sciences-corp
9. Deep Brain Stimulation Devices Market Size, Analysis & Forecast Report 2030, accessed on January 17, 2026, https://www.mordorintelligence.com/industry-reports/deep-brain-stimulation-devices-market
10. Deep Brain Simulation Devices Market Expected to Reach USD 3.5 Billion by 2033, accessed on January 17, 2026, https://www.knobbe.com/blog/deep-brain-simulation-devices-market-expected-reach-usd-35-billion-2033/
11. Deep Brain Stimulation Devices Market Size | Market Research Report 2027 - DelveInsight, accessed on January 17, 2026, https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market
12. Choosing a Deep Brain Stimulation Device | Parkinson's Disease, accessed on January 17, 2026, https://www.michaeljfox.org/news/choosing-deep-brain-stimulation-device
13. FDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology - Jan 8, 2024, accessed on January 17, 2026, https://news.medtronic.com/2024-01-08-FDA-approves-Medtronic-Percept-TM-RC-neurostimulator-with-exclusive-BrainSense-TM-technology
14. First Implant Customer Toolkit | Medtronic, accessed on January 17, 2026, https://www.medtronic.com/content/dam/medtronic-wide/public/united-states/products/neurological/percept-rc-first-implant-customer-toolkit.pdf
15. DBS Product Options | Medtronic, accessed on January 17, 2026, https://www.medtronic.com/en-us/l/patients/treatments-therapies/what-is-dbs/getting/dbs-products.html
16. SenSight™ Directional Lead - Medtronic, accessed on January 17, 2026, https://www.medtronic.com/en-us/healthcare-professionals/products/neurologic

al/deep-brain-stimulation/dbs-therapy-leads/sensight-directional-lead.html
17. Medtronic Australasia Pty Ltd - Percept RC Model B35300 - Brain electrical stimulation system, antitremor (462930) | Therapeutic Goods Administration (TGA), accessed on January 17, 2026, https://www.tga.gov.au/resources/artg/462930
18. Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Feb 24, 2025, accessed on January 17, 2026, https://news.medtronic.com/2025-02-24-Medtronic-earns-U-S-FDA-approval-for-the-worlds-first-Adaptive-deep-brain-stimulation-system-for-people-with-Parkinsons
19. FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy, accessed on January 17, 2026, https://news.medtronic.com/2021-06-07-FDA-Approves-First-of-its-Kind-SenSight-TM-Directional-Lead-System-for-DBS-Therapy
20. Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders[1]+ - Jan 25, 2024, accessed on January 17, 2026, https://abbott.mediaroom.com/2024-01-25-Abbott-Launches-Worlds-Smallest-Rechargeable-System-With-Remote-Programming-Capabilities-to-Treat-Movement-Disorders
21. Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S., accessed on January 17, 2026, https://abbott.mediaroom.com/2021-03-08-Abbott-Introduces-NeuroSphere-TM-Virtual-Clinic-First-of-its-Kind-Remote-Neuromodulation-Patient-Care-Technology-in-the-U-S
22. Boston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System, accessed on January 17, 2026, https://news.bostonscientific.com/2021-01-22-Boston-Scientific-Receives-FDA-Approval-For-The-Vercise-Genus-TM-Deep-Brain-Stimulation-System
23. Vercise Genus™ P8 Information for Prescribers - Boston Scientific, accessed on January 17, 2026, https://www.bostonscientific.com/content/dam/elabeling/nm/pr/92442087-01_Rev_C_Vercise_Genus_P8_DFU_en-US_s.pdf
24. Find The Right DBS System For Your Parkinson's Treatment - Boston Scientific, accessed on January 17, 2026, https://www.dbsandme.com/en/explore-our-systems/our-dbs-systems.html
25. Current and Emerging Treatments for Methamphetamine Use Disorder - PMC, accessed on January 17, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9185770/
26. Sen-Jam Pharmaceutical Advances Addiction Therapeutic Platform with Breakthrough Preclinical Results Leading to Patent for Stimulant Withdrawal - PR Newswire, accessed on January 17, 2026, https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-advances-addiction-therapeutic-platform-with-breakthrough-preclinical-results-leading-to

-patent-for-stimulant-withdrawal-302586919.html
27. CTN-0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder, accessed on January 17, 2026, https://ctnlibrary.org/protocol/ctn0068/
28. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial - University of Texas Southwestern Medical Center, accessed on January 17, 2026, https://utsouthwestern.elsevierpure.com/en/publications/extended-observation-of-reduced-methamphetamine-use-with-combined
29. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial - PubMed, accessed on January 17, 2026, https://pubmed.ncbi.nlm.nih.gov/38856086/
30. Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial) | BMJ Open, accessed on January 17, 2026, https://bmjopen.bmj.com/content/15/2/e092032
31. STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy, accessed on January 17, 2026, https://reporter.nih.gov/search/4qs33DCyy06_U2fk4zc1VA/project-details/9762072
32. NCT05034874 | Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 | ClinicalTrials.gov, accessed on January 17, 2026, https://www.clinicaltrials.gov/study/NCT05034874
33. intervexion therapeutics, llc. - Recipient Information | HHS TAGGS, accessed on January 17, 2026, https://taggs.hhs.gov/Detail/RecipDetail?arg_EntityId=TP4XwsW7%2B%2FT%2FBgGMqwFPGQ%3D%3D
34. protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks - PubMed, accessed on January 17, 2026, https://pubmed.ncbi.nlm.nih.gov/40850924/
35. Solvonis Therapeutics, accessed on January 17, 2026, https://solvonis.com/
36. R&D :: BioCorRx, Inc. (BICX), accessed on January 17, 2026, https://www.biocorrx.com/rd
37. BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition, accessed on January 17, 2026, https://www.biocorrx.com/news-media/press-releases/detail/236/biocorrx-inc-announces-q3-2025-results-second-straight
38. BioCorRx Reports Business Update for the Second Quarter of 2024, accessed on January 17, 2026, https://www.biocorrx.com/news-media/press-releases/detail/232/biocorrx-reports-business-update-for-the-second-quarter-of
39. Unexpected finding could offer new treatment targets for meth addiction - McKnight Brain Institute - University of Florida, accessed on January 17, 2026,

https://mbi.ufl.edu/2025/12/16/unexpected-finding-could-offer-new-treatment-targets-for-meth-addiction/
40. Unexpected finding could offer new treatment targets for meth addiction - UF Health, accessed on January 17, 2026, https://ufhealth.org/news/2025/unexpected-finding-could-offer-new-treatment-targets-for-meth-addiction-2
41. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial - PubMed Central, accessed on January 17, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11193254/
42. May 30, 2025 – Methamphetamine Addiction Trial Launched and more news, accessed on January 17, 2026, https://www.fusfoundation.org/newsletters/may-30-2025-methamphetamine-addiction-trial-launched-and-more-news/